<DOC>
	<DOCNO>NCT02027064</DOCNO>
	<brief_summary>molecular relapse ( 8 ; 21 ) acute myeloid leukemia ( AML ) allogeneic stem cell transplantation ( allo-SCT ) still problem even donor lymphocyte infusion . Interferon seem augment graft-versus-leukemia ( GVL ) effect part patient . study evaluate safety efficacy interferon intervention molecular relapse ( 8 ; 21 ) acute myeloid leukemia ( AML ) allogeneic stem cell transplantation ( allo-SCT )</brief_summary>
	<brief_title>Interferon Intervention Molecular Relapse ( 8 ; 21 ) AML After Allo-HSCT</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>high risk ( 8 ; 21 ) AML molecular relapse alloSCT active graftversushost disease uncontrolled severe infection organ function failure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>